Face-to-face conversation about FDASIA, and other regulations, were invaluable to FDA officials during a recent trip to China.
In a post written for FDA's The Voice blog, Howard Sklamberg, Richard Moscicki, M.D., and Alonza Cruse talked about their trip which included a meeting with Chinese Food and Drug Administration, a tour of a Chinese pharmaceutical manufacturing plant and an event hosted by China’s Pharmaceutical University in Nanjing
"We had productive discussions with the Chinese about how seriously we are committed to making sure that everyone in the drug supply chain – from the companies that make the active ingredients to those that provide the packaging –shares in this collective commitment to quality," the blog post read.
They also wrote, "China is a major provider of many of the active ingredients in finished drug products Americans rely on every day."
For this reason, in part, FDA continues to increase their drug and medical device inspections in China, according to the post.